$0.74
0.74% yesterday
Nasdaq, Aug 21, 10:00 pm CET
ISIN
US04962H5063
Symbol
ATOS

Atossa Genetics Inc. Stock price

$0.74
-0.10 12.34% 1M
-0.05 6.44% 6M
-0.20 21.19% YTD
-0.65 46.47% 1Y
-0.27 26.34% 3Y
-2.64 77.99% 5Y
-152.26 99.51% 10Y
-863.26 99.91% 20Y
Nasdaq, Closing price Thu, Aug 21 2025
+0.01 0.74%
ISIN
US04962H5063
Symbol
ATOS
Industry

Key metrics

Basic
Market capitalization
$96.1m
Enterprise Value
$38.2m
Net debt
positive
Cash
$57.9m
Shares outstanding
129.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.7
Financial Health
Equity Ratio
93.5%
Return on Equity
-35.7%
ROCE
-54.9%
ROIC
-1,025.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-31.7m | -
EBIT
$-31.7m | $-32.5m
Net Income
$-28.7m | $-31.3m
Free Cash Flow
$-25.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-3.7% | -
EBIT
-3.7% | -17.6%
Net Income
-10.8% | -22.7%
Free Cash Flow
-34.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
3.0%
Employees
15
Rev per Employee
$0.0
Show more

Is Atossa Genetics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Atossa Genetics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Atossa Genetics Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Atossa Genetics Inc. forecast:

Buy
90%
Hold
10%

Financial data from Atossa Genetics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
3% 3%
-
- Research and Development Expense 16 16
6% 6%
-
-32 -32
4% 4%
-
- Depreciation and Amortization 0.02 0.02
0% 0%
-
EBIT (Operating Income) EBIT -32 -32
4% 4%
-
Net Profit -29 -29
11% 11%
-

In millions USD.

Don't miss a Thing! We will send you all news about Atossa Genetics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Atossa Genetics Inc. Stock News

Neutral
PRNewsWire
2 days ago
Monotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025 Topline results anticipated in 2026  Positions Atossa for transition into registrational Phase 3 development SEATTLE , Aug. 20, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, announced...
Neutral
PRNewsWire
10 days ago
FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required Strong I-SPY2 Results Reinforce Efficacy of Atossa's Monotherapy at 3-weeks SEATTLE , Aug. 12, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company deve...
Neutral
PRNewsWire
24 days ago
SEATTLE , July 29, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced positive written feedback from the U.S. Food and Drug Administration (FDA) regarding the company's proposed dose optimization trial of (Z)-endoxifen for the treatment of estrogen receptor positive (ER+), human e...
More Atossa Genetics Inc. News

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Head office United States
CEO Steven Quay
Employees 15
Founded 2008
Website atossatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today